Last reviewed · How we verify
Hydroxymethylquinoxalindioxyde
Hydroxymethylquinoxalindioxyde is a quinoxaline derivative that likely acts as an antioxidant or free radical scavenger to reduce oxidative stress-related cellular damage.
At a glance
| Generic name | Hydroxymethylquinoxalindioxyde |
|---|---|
| Also known as | Dioxidin |
| Sponsor | Valenta Pharm JSC |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Quinoxaline dioxides are known to possess antioxidant properties through their ability to neutralize reactive oxygen species and free radicals. The hydroxymethyl substitution may enhance bioavailability or target tissue penetration. This mechanism suggests potential utility in conditions characterized by oxidative stress pathology.
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Dioxidin Versus Miramistin in Superficial Pyoderma (PHASE3)
- Safety and Pharmacokinetics of Dioxidin, Solution for Topical and External Use, 0.25 mg/ml and Dioxidin, Solution for Infusion and External Use, 5 mg/ml in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hydroxymethylquinoxalindioxyde CI brief — competitive landscape report
- Hydroxymethylquinoxalindioxyde updates RSS · CI watch RSS
- Valenta Pharm JSC portfolio CI